• 首页期刊简介编委会刊物订阅专栏专刊电子刊广告合作联系我们English
引用本文:王勉,胡静静,蔡兆斌.沙库巴曲缬沙坦在心血管疾病中的多效性研究进展[J].中国现代应用药学,2019,36(17):2236-2239.
WANG Mian,HU Jingjing,CAI Zhaobin.Advances Research of Sacubitril-valsartan's Pleiotropic Effects on Cardiovascular Diseases[J].Chin J Mod Appl Pharm(中国现代应用药学),2019,36(17):2236-2239.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2133次   下载 898 本文二维码信息
码上扫一扫!
分享到: 微信 更多
沙库巴曲缬沙坦在心血管疾病中的多效性研究进展
王勉1, 胡静静1, 蔡兆斌2
1.浙江中医药大学, 杭州 310053;2.杭州市西溪医院, 杭州 310023
摘要:
沙库巴曲缬沙坦是全球首个血管紧张素受体脑啡肽酶抑制剂,它在拮抗血管紧张素Ⅱ受体的同时抑制脑啡肽酶的降解,大量临床试验资料表明它有潜力用于多种心血管疾病的治疗。熟悉沙库巴曲缬沙坦的临床应用,对更好地开发沙库巴曲缬沙坦具有深远意义。本文检索近年来国内外相关的文献报道,对沙库巴曲缬沙坦的药理作用及用于慢性射血分数降低的心力衰竭、慢性射血分数保留的心力衰竭的治疗以及其他方面如高血压、慢性肾功能不全、心肌梗死后的临床治疗及动物试验的相关进展进行综述。
关键词:  沙库巴曲缬沙坦  药理机制  心力衰竭  高血压  慢性肾功能不全
DOI:10.13748/j.cnki.issn1007-7693.2019.17.024
分类号:
基金项目:
Advances Research of Sacubitril-valsartan's Pleiotropic Effects on Cardiovascular Diseases
WANG Mian1, HU Jingjing1, CAI Zhaobin2
1.Zhejiang Chinese Medical University, Hangzhou 310053, China;2.Xixi Hospital of Hangzhou, Hangzhou 310023, China
Abstract:
Sacubitril-valsartan is the first-in-class angiotensin receptor-neprilysin inhibitor, with dual action mechanism that is antagonistic angiotensin Ⅱ receptor while inhibiting neprilysin. Datas from clinical studies of Sacubitril-valsartan suggest it has potential for the treatment of a variety of cardiovascular diseases. Familiar with the clinical application of Sacubitril-valsartan, has profound significance for the better development of it. According to the correlative reports in recent years, this paper reviewed it's pharmacologica mechanism and clinicalor animal trials of the heart failure with reduced ejection fraction and heart failure with preserved ejection fraction and other aspects such as hypertension, chronic renal impairment, and following myocardial infarction.
Key words:  Sacubitril-valsartan  pharmacological mechanism  ejection fraction  hypertension  chronic renal impairment
扫一扫关注本刊微信